A cost-effectiveness analysis of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy.

Journal of clinical hypertension (Greenwich, Conn.)

Volumn 9, Issue 10, 2007, Pages 751-759

  Stafylas, Panagiotis C ^a   Sarafidis, Pantelis A ^a   Grekas, Dimitrios M ^a   Lasaridis, Anastasios N ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CHRONIC KIDNEY FAILURE; COST BENEFIT ANALYSIS; DIABETIC NEPHROPATHY; DRUG EFFECT; ECONOMICS; GREECE; HUMAN; META ANALYSIS; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COST-BENEFIT ANALYSIS; DIABETIC NEPHROPATHIES; GREECE; HUMANS; KIDNEY FAILURE, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 38849165505     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2007.07182.x     Document Type: Article

References (0)